Bioelectronics Corp (BIEL)

[shadolane]

As a long since 2009 I have the following comments:

The SEC action isn't being taken just for the fun of it. Something must have triggered the investigation and suit. We will see how that plays out.

Of more concern is the flat lined product sales in spite of many outlets having been added in the UK and the continuation of those outlet additions. And that doesn't even include any of the other markets that the company is selling into. The question here is what does that mean? To me it potentially means that repeat buying may not be happening either because the product works and can be used for extended periods of time or that the product doesn't work well enough to buy it again.

Product sales and sales growth is needed to make the company viable.

I am skeptical that the Braun action and the potential FDA clearance will be the silver bullet salvation for sales or pps.

Sorry folks, this isn't being negative. Just objective thinking about business issues. After all, I'm invested too.